Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer

Similar Items

• Need for Caution in the Diagnosis of Radiation Pneumonitis During the COVID-19 Pandemic
  od: Shaverdian, Narek, i dr.
  Izdano: (2020)
• Thoracic Radiation Therapy During Coronavirus Disease 2019: Provisional Guidelines from a Comprehensive Cancer Center within a Pandemic Epicenter
  od: Wu, Abraham J., i dr.
  Izdano: (2020)
• Treatment planning and outcomes effects of reducing the preferred mean esophagus dose for conventionally fractionated non‐small cell lung cancer radiotherapy
  od: Yorke, Ellen D., i dr.
  Izdano: (2021)
• The Impact of Durvalumab on Local Regional Control in Stage III Non-Small Cell Lung Cancers Treated with Chemoradiation and on KEAP1/NFE2L2 Mutant Tumors
  od: Shaverdian, Narek, i dr.
  Izdano: (2021)
• Clinical and Dosimetric Predictors of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Undergoing Post-Operative Radiation Therapy
  od: Shepherd, Annemarie, i dr.
  Izdano: (2020)